Sanofi has received approval from the US FDA for a supplemental biologic licence application for Tzield, allowing its use to delay stage 3 T1D onset in children as young as one year diagnosed with ...

This Durham-based facility will be AbbVie’s first manufacturing site in the state, and will become a centre of excellence for SVP production.

In global nephrology studies, aligning biology, design, operations, and interpretation across regions is essential for avoiding small missteps that could amplify through development.

MSD and Google Cloud have formed a multi-year partnership, investing up to $1bn, to advance agentic AI enterprise transformation.

Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.

GlobalData analysts forecast a blockbuster future for Idvynso, though they note it is unlikely it will displace market dominator, Biktarvy.

Ray's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.

The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly.

Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.

Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.